Clinical trials: Hepatitis C Virus (HCV)
Hepatitis C
A Community-based, Behavioral Intervention to Improve Screening for Hepatitis C Among High-risk Young Adults in Wisconsin
The goal of this study is to evaluate the effectiveness of a brief, computerized behavioral intervention for promoting screening for hepatitis C and reducing risky behavior for people who inject drugs (PWID).
- Trial name
- Hep-Net (NCT02474043)
- Testing
- Hep-Net Intervention, Usual Care
- Volunteers
- 235 people
- Sponsor
- University of Wisconsin, Madison
Chronic Hepatitis C
A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects
The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of BMS-791325 in subjects with chronic hepatitis C infection
- Trial name
- NCT00664625
- Testing
- BMS-791325
- Where
- 6 sites in United States, Argentina
- Volunteers
- 24 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus Infection
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection
This primary objectives of the study are to evaluate the safety, tolerability, and efficacy of voxilaprevir (VOX) plus sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) ± ribavirin (RBV) in adults with chronic…
- Trial name
- NCT02378935
- Testing
- VOX, SOF/VEL, RBV
- Where
- 34 sites in United States, New Zealand and 1 more
- Volunteers
- 205 people
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus, Hepatitis C
Computer-based Intervention for Alcohol-using HIV/HCV+ Women
The study harnessed the multidisciplinary expertise of our research team to develop a brief, computer-based, alcohol reduction intervention tailored for HIV/HCV co-infected women and evaluate its efficacy.
- Conditions
- Human Immunodeficiency Virus, Hepatitis C, Alcohol Abuse
- Trial name
- NCT03362476
- Testing
- Computer-based alcohol reduction intervention, Brief clinician-delivered MET, Standard of care
- Where
- 2 sites in United States, Russia
- Volunteers
- 200 people
- Sponsor
- New York University
Hepatitis C Infection
Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks
The aim of the study is to evaluate in clinical practice the efficacy and safety of ombitasvir/paritaprevir/ ritonavir and dasabuvir administered for 8 weeks in treatment-naïve participants with genotype 1b hepatitis C virus…
- Trial name
- 3D8 (NCT03122132)
- Testing
- ombitasvir/paritaprevir/ritonavir 8 weeks, dasabuvir 8 weeks
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Hepa C
Hepatitis C, HIV
Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers
The investigators believe that boceprevir's drug concentrations will be reduced when administered in combination with etravirine.
- Trial name
- NCT01427504
- Testing
- boceprevir; etravirine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Viral Hepatitis B, Viral Hepatitis C
Therapeutic Option for Hepatitis B and C: a French Cohort
The cohort will integrate clinical, genetic, pharmacogenomics, environmental, biomarkers and behavioral data in a large number of patients and will be a leading equipment for crossdisciplinary and translational research on…
- Trial name
- HEPATHER (NCT01953458)
- Where
- France
- Volunteers
- 20,902 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis C Virus, Hepatitis C Virus
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection
The purpose of this phase 3, multicenter study is to evaluate the efficacy and safety of ABT-493/ABT-530 in Japanese adults with chronic Hepatitis C Virus (HCV)-infected, HCV direct-acting antiviral agent (DAA) treatment-naïve…
- Trial name
- CERTAIN-1 (NCT02707952)
- Testing
- ABT-493/ABT-530, OBV/PTV/r
- Volunteers
- 295 people
- Sponsor
- AbbVie
Chronic Hepatitis C
A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects
The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
- Trial name
- NCT01511432
- Testing
- telaprevir formulation A, telaprevir Formulation B, telaprevir Formulation C
- Where
- 2 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C
Re-treatment of HCV Following DAA Failure
HCV infection is treated with oral drugs, termed as 'direct-acting anti-viral agents' (DAAs). In India, four DAAs are available (sofosbuvir [SOF], daclatasvir [DCV], ledipasvir [LDV] and velpatasvir [VEL]).
- Trial name
- NCT03483987
- Testing
- Sof+Ledi+R arm, Sof+Ledi+R+Peg-IFN arm, Sof+Dacla+R arm
- Where
- 2 sites in India
- Volunteers
- 18 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Chronic Hepatitis C Infection
Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
This is a multi-centre prospective longitudinal cohort study with the aim of collecting and storing clinical data, patient blood, DNA and PBMCs to examine outcomes related to drug resistance, drug monitoring and host genetics in…
- Trial name
- SEARCH-C (NCT02065999)
- Where
- 2 sites in Australia
- Volunteers
- 100 people
- Sponsor
- Kirby Institute
Purpura, Thrombocytopaenic, Idiopathic
Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment
The main purpose of this study is to compare how one 50mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe liver problems.
- Trial name
- NCT00359463
- Testing
- eltrombopag
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C
Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC)
The overall aim of this study is to evaluate the prevalence of cognitive impairments and brain anomalies in Chronic Hepatitis C infected individuals and to investigate likely changes in cognition and brain structure and function…
- Trial name
- CICHepC (NCT02745132)
- Testing
- Neuropsychological evaluation and Brain MRI
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Hepatitis C
Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA
Sofosbuvir plus daclatasvir with or without ribavirin is one of the currently recommended treatment option for chronic hepatitis C.
- Trial name
- NCT03318887
- Testing
- Sofosbuvir/daclatasvir with or without ribavirin
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Hospices Civils de Lyon
Hepatitis C, Cirrhosis
Intravenous Interferon During Liver Transplant
The main goal of this study is to prevent liver allograft infection with Hepatitis C virus in hepatitis C positive patients undergoing liver transplantation.
- Trial name
- NCT01192698
- Testing
- IV interferon
- Volunteers
- 15 people
- Sponsor
- Wake Forest University Health Sciences
Hepatitis C, HIV
Monitoring Liver Disease Progression in Hepatitis C/HIV Co-infected Patients With No-to-moderate Fibrosis, in Phnom Penh, Cambodia
Data on the progression of liver fibrosis in patients co-infected with HIV taking effective suppressive antiretroviral therapy with no fibrosis or mild-to-moderate fibrosis at baseline are scarce.
- Trial name
- HCV-Monitoring (NCT02628691)
- Testing
- Liver fibrosis progression
- Where
- Cambodia
- Volunteers
- 70 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Hepatitis C, Chronic
ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)
This is a Phase 4, retrospective and observational, multicenter, national (Brazil), open, noncomparative, and nonrandomized study, which does not have visits. This study will be conducted in accordance to Good Clinical Practices.
- Trial name
- ATHENAS (NCT00856024)
- Testing
- Peginterferon alfa-2b, Ribavirin
- Volunteers
- 902 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Chronic, Hepatitis C
Implementation of a Re-engagement Program for Hepatitis C Patients Lost to Follow-up in Argentina.
Hepatitis C virus (HCV) is a leading cause of morbidity and mortality worldwide. This infection continues to represent a major global public health concern.
- Trial name
- NCT06373198
- Testing
- standard of care
- Volunteers
- 800 people
- Sponsor
- Hospital El Cruce
Hepatitis C, Chronic
Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4
To evaluate the safety and efficacy of a daily, fixed-dose, 8-week course combination of Elbasvir/Grazoprevir in treatment-naïve, non-cirrhotic patients who are mono-infected with hepatitis C, genotype 4.
- Trial name
- ELEGANT-4 (NCT03578640)
- Testing
- Elbasvir, Grazoprevir 50-100Mg Oral Tablet
- Where
- Saudi Arabia
- Volunteers
- 30 people
- Sponsor
- King Fahad Medical City
Chronic Hepatitis C
Pharmacogenomics Study on IL28B Genetic Variants in Chinese Children With Hepatitis C Virus Infection
The aim of this study is to investigate the relationships between interleukin 28B genetic variants and the response to treatment of chronic hepatitis C in Chinese children.
- Trial name
- NCT01607021
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing 302 Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.